Pharming launches Joenja in Japan, expanding APDS treatment to patients aged 4 and older

PUBT · 2d ago
Pharming launches Joenja in Japan, expanding APDS treatment to patients aged 4 and older
  • Pharming launched Joenja (leniolisib) commercially in Japan for activated PI3K delta syndrome patients aged 4 and older.
  • Launch followed inclusion on Japan’s National Health Insurance drug price list, opening reimbursed access in a new market.
  • Japan becomes the first market with commercial Joenja availability for children aged 4 to 11.
  • OrphanPacific holds Japanese marketing authorization, handling supply and distribution under an agreement with Pharming.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharming Group NV published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.